Belite Bio, Inc

Hello, and thank you for joining us to discuss Be Light Bio's third quarter 2024 financial results. Joining the call today are Dr. Tom Lin, Chairman and CEO of Be Light Bio, Dr. Hendrik Scholl, Chief Medical Officer, Dr. Nathan Mata, Chief Scientific Officer, and Hao-Wan Zhang, Chief Financial Officer. Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may vary materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Please note that you can submit questions throughout the call by clicking on the Q&A box at the bottom of your screen. We'll respond to your questions following our prepared remarks. Now I'll turn the call over to Dr. Lin.

Thank you for joining our third quarter conference call. Before diving into the details of this quarter's performance and status of our pipeline, I would like to introduce an exciting addition to our leadership team. It is my pleasure to welcome Dr. Hendrick Shaw, our new chief medical officer, to the call. Professor Shaw is the world's foremost expert in stardust disease and age-related macular degeneration. He has pioneered some of the most significant ophthalmology and retinal disease advancements of our time. including the world's largest ever natural history study of Stargardt's disease. We're thrilled to have him lead our clinical program at such a pivotal time, I feel like, and I'm certain his expertise and dedication will be instrumental in advancing our efforts to bring much-needed treatments to patients living with Stargardt's disease and dry AMD. Dr. Shou, welcome.

Thank you, Tom. I'm honored to be joining Belight Bio at a time when the company's clinical programs are showing such promise. Having served as the chair of the Data and Safety Monitoring Board for Belight's Phase 2 and Phase 3 Stargardt disease trials, I feel immensely confident in Tinlaraban's potential. I have dedicated my career by improving the lives of people suffering from serious retinal and specifically macular diseases, which are almost always debilitating and have a profound negative impact on the people's quality of life. I'm deeply impressed by Belight Bio's pioneering approach to Stager disease and late-dry AMD, which have historically lacked effective treatment options. Having seen firsthand the toll these diseases can have, I look forward to working with our talented team to drive our clinical programs forward and hopefully bring transformative therapies to patients in need.